Vosoritide’s first phase 2 study shows increased growth in children with hypochondroplasia

Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children’s National Hospital.

HHS Announces Funding Opportunity to Improve AI-Powered Healthcare & Behavioral Health IT

What You Should Know: – The U.S. Department of Health and Human Services (HHS), through the Office of the National Coordinator for Health Information Technology

May 14, 2024

Lilly unveils more positive late-stage data for its once-weekly insulin

On Thursday, Eli Lilly dropped more data for its once-weekly insulin candidate in adults with type 2 diabetes. In two Phase 3 trials, dubbed QWINT

September 6, 2024

Researchers develop T cell growth method that enhances cancer-fighting ability in melanoma model

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

January 31, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.